Biotech companies struggle to secure final-stage funding to complete construction and reach operational capacity

Biotech firms with nearly-completed facilities face construction halts when they can't secure final funding rounds, leaving expensive infrastructure incomplete and delaying revenue generation. Companies like Liberation Bioindustries are stuck in a funding gap where traditional investors won't commit to bridge the last $25M needed, forcing them to pause operations and burn cash on idle facilities. Current funding solutions fail because late-stage biotech requires specialized investors who understand the sector's long development timelines and regulatory risks.